Tramadol, buy tramadol, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, weight loss, hair loss, hair growth, hair regrowth, hair restoration, baldness, Rx Online, pharmaceuticals, DHEA, Lutein, Prescription, Prescription drug, prescription medications, Propecia.

References: Hair growth and hair loss

Int J Radiat Biol. 1992 Apr;61(4):533-7.
Topical or systemic 16, 16 dm prostaglandin E2 or WR-2721 (WR-1065) protects mice from alopecia after fractionated irradiation.

Geng L, Hanson WR, Malkinson FD.

Department of Dermatology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612-3864.

Our previous studies in mice demonstrated that systemic or topical 16,16 dm PGE2 protected against single dose radiation-induced hair loss. We have now investigated prostaglandin, or WR-2721, protection against murine alopecia produced by varying doses and schedules of fractionated radiation. On days one to eight after hair was plucked from the thighs of B6D2F1 mice, groups of 6 animals each were given daily exposures of 4.0 or 4.5 Gy for 5 days; 2.5, 3.5, 4.5 or 5.5 Gy for 10 days; or 2 Gy for 15 days. One hour before irradiation each mouse received 10 microgram 16,16 dm PGE2, either by subcutaneous injection into the neck or topical application, 8 mg WR-2721 by injection, or 0.3 mg WR-1065 by topical application. Three weeks later counts of regrowing hairs were recorded from excised skin samples. For the radioprotectors used, hair regrowth was increased 25-100% in the various radiation groups in comparison to irradiated-only control sites. In some studies with the radioprotector given systemically, WR-2721 afforded slightly greater radioprotection than 16,16 dm PGE2. The two compounds were essentially equally radioprotective in the topical application studies. Since both systemic and topical applications of the agents tested enhanced hair regrowth following radiation, we conclude that clinical use of these compounds may provide some protection of hair follicles, and perhaps other tissues, lying within a radiation therapy field.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1349335&dopt=Abstract

J Interferon Cytokine Res. 2003 Aug;23(8):433-9.
Induction of hair regrowth in the alopecia site of IFN-gamma knockout mice by allografting and IFN-gamma injection into the transplantation site.

Hirota R, Tajima S, Yoneda Y, Okada M, Tashiro J, Ueda K, Kubota T, Yoshida R.

Department of Physiology, Osaka Medical College, Takatsuki 569-8686, Japan.

We previously demonstrated that around 6 weeks of age most of the interferon-gamma (IFN-gamma)(-/-) but none of the IFN-gamma(+/+) C57BL/6 mice began to lose hair in their dorsal or occipital areas or both and that a single s.c. injection of IFN-gamma into IFN-gamma(-/-) mice at 3 but not at 8 weeks of age (or later) could protect all the mice from alopecia. Here, we report hair regrowth in the alopecia site of IFN-gamma(-/-) mice at 8 weeks of age (or later) by the combination of IFN-gamma and allografting. Skin or tumor allografting and IFN-gamma injections into the transplantation site induced hair regrowth in the alopecia site of IFN-gamma(-/-) mice at 8-66 weeks of age, whereas IFN-gamma injections into the hairless site or allografting alone was ineffective in causing the hair regrowth. Histologic findings showed that the hair cycle in the region of alopecia of IFN-gamma(-/-) mice was blocked at the anagen stage and that in the IFN-gamma(-/-) mice treated with IFN-gamma and allografting, the cycle was at the telogen stage. The therapeutic effects were maintained for >1 year.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=13678431&dopt=Abstract [PubMed - in process]

Dermatology. 1992;184(3):198-201.
Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after an additional follow-up period of 19 months.

van der Steen PH, Boezeman JB, Happle R.

Department of Dermatology, University of Nijmegen, The Netherlands.

Within a group of 139 patients previously studied during treatment for alopecia areata with diphenylcyclopropenone (DCP), hair growth was re-evaluated after a period of 19 months following completion of our previous study. Fifty-four patients treated with DCP had total and 6 had partial but cosmetically acceptable regrowth. Twenty-five patients with total regrowth had stopped DCP treatment for a mean period of 15 months and had not relapsed. Nineteen of 28 patients who still applied DCP were in the process of stepwise discontinuation of treatment. Fifteen patients had subsequently been treated with squaric acid dibutylester (SADBE) after having acquired 'tolerance' to DCP; at the time of re-evaluation 3 of these patients had complete regrowth, and 4 patients had partial but cosmetically acceptable regrowth. Topical immunotherapy with DCP and SADBE had resulted in total regrowth in 57/139 patients (41.0%) and in partial but cosmetically satisfactory regrowth in 10/139 patients (7.2%). The type of involvement and duration of alopecia areata were factors of prognostic significance.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1392112&dopt=Abstract

Buy Lipitor Online

Herbs and Pharmaceuticals Online || Hair Million herbal formula for hair loss and hair growth || Hair growth research references || E-Mail Us